Keryx says Zerenex found safe across all treatment doses

By Elaine Rigoli

Tampa, Fla., June 29 - Keryx Biopharmaceuticals, Inc. announced positive final results from the phase 2, placebo-controlled, dose-ranging study of the effects of Zerenex on serum phosphate in patients with end-stage renal disease, with investigators concluding that Zerenex has an acceptable safety and tolerability profile at the 2, 4, and 6 g/day dose.

The optimum dose of Zerenex in this study was 6 g per day at which dose it appeared to be efficacious, safe and well-tolerated as treatment for hyperphosphatemia in hemodialysis patients, according to a news release.

Additionally, the investigators found that Zerenex therapy for up to 28 days had no statistically significant effect on serum iron, ferritin, transferring saturation, or total iron binding capacity.

New York-based Keryx is focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.